A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Clinical trial NCT07054567 · RECRUITING
Trial details
- NCT number
- NCT07054567
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-21
- Primary completion
- 2027-05-01
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.